Phase II European trial of DPX-Survivac (EMD 640744) + temozolomide in patients with maximally resected newly-diagnosed glioblastoma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 03 May 2018
At a glance
- Drugs EMD 640744 (Primary) ; Dendritic cell vaccines; Temozolomide
- Indications Glioblastoma
- Focus Pharmacodynamics
- 03 May 2018 According to an IMV media release, Immunovaccine has changed its name to IMV.
- 20 Jan 2014 This trial is expected to start in the first half of 2014, according to a Immunovaccine media release.
- 04 Jun 2013 New trial record